Left Ventricular HypertrophyNCT07380893
Left Ventricular Hypertrophy in CKD Patients
An observational study of Left Ventricular Hypertrophy, run by Sohag University.
Trial summary
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Left Ventricular Hypertrophy
- What is being tested?
- transthoracic echocardiography
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 15 Jan 2026to 15 Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: study population is adults age (18-75)years, diagnosed with CKD stage 3-5 .
Who may be able to join
- Adults (≥18 years) diagnosed with CKD stages 3-5.
- Stable clinical condition for ≥3 months.
- Anemia (Hb <10 g/dL) for cohort phase.
- Willingness to participate and provide informed consent.
Who cannot join
- Valvular or ischemic heart disease.
- Uncontrolled hypertension (BP >180/110 mmHg).
- Acute coronary syndrome or decompensated heart failure in the past 3 months.
- Malignancy or active infection
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Marwa Z Elsayed, MD contact
About this study
Official title: Prevalence of Left Ventricular Hypertrophy (LVH) in CKD Patients and Effect of Erythropoietin Therapy
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
The main question it aims to answer is:
Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?
Read the detailed description
The prevalence of LVH in CKD patients has been reported to range from 40% to 75%, depending on disease stage, blood pressure control, and diagnostic methodology. LVH typically develops early and worsens with CKD progression, reflecting the close interplay between renal dysfunction and cardiac remodeling.
Anemia is a prominent non-hemodynamic contributor to LVH in CKD. Reduced erythropoietin (EPO) production by the damaged kidneys, together with iron deficiency and chronic inflammation, leads to decreased oxygen delivery, compensatory cardiac output elevation, and subsequent ventricular hypertrophy.
Given the strong association between CKD, anemia, and cardiovascular remodeling, investigating the prevalence of LVH and the effect of erythropoietin therapy on left ventricular mass among CKD patients can provide critical insights into optimizing cardiovascular risk management in this high-risk group.
this study will be conducted to :
- To determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital.
- To assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
A total of 100 CKD patients will be included.
- Phase I : All CKD patients will undergo echocardiographic evaluation to determine the prevalence of LVH.
- Phase II : Among anemic CKD patients with LVH receiving erythropoietin therapy , will be followed for 6 months
- Conditions
- Left Ventricular Hypertrophy
- Being tested
- transthoracic echocardiography
- Medical subject headings
- Hypertrophy, Left Ventricular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transthoracic echocardiographyRadiation
Standard transthoracic echocardiography will be performed for all participants, measuring:
- Left ventricular end-diastolic diameter (LVEDD)
- Interventricular septal thickness (IVSD)
- Posterior wall thickness (PWD)
- Left ventricular mass (LVM)
- Left ventricular mass index (LVMI = LVM/body surface area)
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in LVMI following erythropoietin therapy in anemic CKD patients.
Measured: - baseline transthoracic echocardiography will be performed for all group study.
Secondary outcomes (1)
Association between hemoglobin level and LVMI.
Measured: 6 months of erythropoitin therapy , transthoracic echocardiography will be performed for all group study.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2026
- Study start15 Jan 2026 (estimated)
- Primary completion15 Jun 2026 (estimated)
- Study completion15 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Left Ventricular HypertrophyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Khaled Mohamed Mohamedin, Sohag University
- Investigators
- Amal Kh Ahmed, MD, Study chair, Sohag university- faculty of medicine - internal medicine department
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07380893
- Sponsor's protocol ID
- Soh-Med--25-11-7MS
- Status last verified
- Jan 2026
- First submitted
- 30 Dec 2025
- Last updated
- 2 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Left Ventricular Hypertrophy (LVH) in CKD Patients and Effect of Erythropoietin Therapy
- ClinicalTrials.gov ID
- NCT07380893
- Acronym / sponsor ID
- Soh-Med--25-11-7MS
- Conditions
- Left Ventricular Hypertrophy
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 15 Jan 2026 (estimated)
- Primary completion
- 15 Jun 2026 (estimated)
- Study completion
- 15 Jul 2026 (estimated)
- First posted
- 2 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
The main question it aims to answer is:
Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?
Detailed description
The prevalence of LVH in CKD patients has been reported to range from 40% to 75%, depending on disease stage, blood pressure control, and diagnostic methodology. LVH typically develops early and worsens with CKD progression, reflecting the close interplay between renal dysfunction and cardiac remodeling.
Anemia is a prominent non-hemodynamic contributor to LVH in CKD. Reduced erythropoietin (EPO) production by the damaged kidneys, together with iron deficiency and chronic inflammation, leads to decreased oxygen delivery, compensatory cardiac output elevation, and subsequent ventricular hypertrophy.
Given the strong association between CKD, anemia, and cardiovascular remodeling, investigating the prevalence of LVH and the effect of erythropoietin therapy on left ventricular mass among CKD patients can provide critical insights into optimizing cardiovascular risk management in this high-risk group.
this study will be conducted to :
- To determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital.
- To assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
A total of 100 CKD patients will be included.
- Phase I : All CKD patients will undergo echocardiographic evaluation to determine the prevalence of LVH.
- Phase II : Among anemic CKD patients with LVH receiving erythropoietin therapy , will be followed for 6 months
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- study population is adults age (18-75)years, diagnosed with CKD stage 3-5 .
Key inclusion criteria (4 listed)
- Adults (≥18 years) diagnosed with CKD stages 3-5.
- Stable clinical condition for ≥3 months.
- Anemia (Hb <10 g/dL) for cohort phase.
- Willingness to participate and provide informed consent.
Key exclusion criteria (4 listed)
- Valvular or ischemic heart disease.
- Uncontrolled hypertension (BP >180/110 mmHg).
- Acute coronary syndrome or decompensated heart failure in the past 3 months.
- Malignancy or active infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transthoracic echocardiographyStandard transthoracic echocardiography will be performed for all participants, measuring: * Left ventricular end-diastolic diameter (LVEDD) * Interventricular septal thickness (IVSD) * Posterior wall thickness (PWD) * Left ventricular mass (LVM) * Left ventricular mass index (LVMI = LVM/body surface area) | Radiation | – |
Primary outcome
Change in LVMI following erythropoietin therapy in anemic CKD patients.
Time frame: - baseline transthoracic echocardiography will be performed for all group study.
1 secondary outcome
Association between hemoglobin level and LVMI.
Time frame: 6 months of erythropoitin therapy , transthoracic echocardiography will be performed for all group study.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2026.
Related trials for Left Ventricular Hypertrophy
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Active, not recruiting
Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS
Aortic Valve Stenosis, Hypertrophy, Left Ventricular
Not yet recruiting
Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD)
Fabry Disease
RecruitingPhase 2
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Danon Disease
RecruitingPhase 2
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marwa Z Elsayed, MD contact
Amal Kh Ahmed, MD study chair
Sohag university- faculty of medicine - internal medicine department
Questions about this trial
What is this clinical trial studying?
An observational study of Left Ventricular Hypertrophy, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact khaled M Mohamedein, MBCHB (+201507290373, drkhaledmmm1984@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in LVMI following erythropoietin therapy in anemic CKD patients. (time frame: - baseline transthoracic echocardiography will be performed for all group study.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2026.